




**SUPPLEMENTARY FIGURES**




**Supplementary Figure 1. Meta-analysis of site-specific SIRs in CRC survivors.**




Supplementary Figure 2. The pooled SIR for second prostate cancer in CRC survivors with different restriction to lag time.




Supplementary Figure 3. The pooled SIR for second breast cancer in CRC survivors with different restriction to lag time.




Supplementary Figure 4. The pooled SIR for second ovary cancer in CRC survivors with different restriction to lag time.




Supplementary Figure 5. The pooled SIR for second neoplasm of stomach in CRC survivors with different restriction to lag time.



Supplementary Figure 6. The pooled SIR for second bladder cancer in CRC survivors with different restriction to lag time.




Supplementary Figure 7. The pooled SIR for second kidney cancer in CRC survivors with different restriction to lag time.



Supplementary Figure 8. The pooled SIR for second thyroid cancer in CRC survivors with different restriction to lag time.





Supplementary Figure 9. The pooled SIR for second neoplasm of bone and soft tissue in CRC survivors with different restriction to lag time.